We hypothesize that different breast cancer subtypes (Luminal A, Luminal B, HER2+, and Basal) may possess unique RNA splicing signatures for genes of the sphingolipid pathway, and post-transcriptional regulation (alternative splicing) of these genes, especially ceramide synthases, may contribute to breast cancer development. This evidence concerns the gene ERBB2 and breast carcinoma.